Title:
NEW CORONAVIRUS VACCINE AND METHOD FOR DESIGNING AND OBTAINING A VIRUS VACCINE
Document Type and Number:
WIPO Patent Application WO/2023/031306
Kind Code:
A3
Abstract:
The present invention relates to a mutant receptor-binding domain (mRBD) of a coronavirus (mRBD-CORONA) or a fragment thereof and mutant spike protein of the coronavirus (CORONA-mSpike) or a fragment thereof comprising the CORONA-mRBD or the fragment thereof. Furthermore, the present invention relates to a polypeptide or protein comprising the mRBD-CORONA or the fragment thereof or CORONA-mSpike or the fragment thereof and a nucleic acid comprising a nucleotide sequence encoding for the mRBD-CORONA or the fragment thereof or the CORONA-mSpike or the fragment thereof. Furthermore, the present invention relates to a vaccine composition comprising one or more CORONA-mRBDs or fragments thereof, one or more CORONA- mSpikes, one or more polypeptides or proteins and/or one or more nucleic acids according to the present invention. Furthermore, the present invention relates to the one or more CORONA-mRBDs or fragments thereof, the one or more CORONA-mSpikes, the one or more polypeptides or proteins, the one or more nucleic acids and/or the vaccine composition according to the present invention for use in the prevention and/or treatment of diseases caused by coronaviruses in a subject. Furthermore, the present invention relates to a method for designing and/or obtaining an active ingredient for a vaccine composition and to a VIRUS-mRBD or a fragment thereof designed and/orobtained by the method for obtaining the VIRUS-mRBD according to the present invention.
Inventors:
DE LA ROSA KATHRIN (DE)
LEBEDIN MIKHAIL (DE)
RATSWOHL CHRISTOPH (DE)
VAZQUEZ GARCIA CLARA (DE)
SILVIS CASPER (DE)
EYER KLAUS (CH)
SIGVALDADÓTTIR INGIBJÖRG (CH)
OLSSON SIMON (SE)
LEBEDIN MIKHAIL (DE)
RATSWOHL CHRISTOPH (DE)
VAZQUEZ GARCIA CLARA (DE)
SILVIS CASPER (DE)
EYER KLAUS (CH)
SIGVALDADÓTTIR INGIBJÖRG (CH)
OLSSON SIMON (SE)
Application Number:
PCT/EP2022/074255
Publication Date:
April 13, 2023
Filing Date:
August 31, 2022
Export Citation:
Assignee:
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE)
ETH ZUERICH (CH)
ETH ZUERICH (CH)
International Classes:
C07K14/005; A61K39/12; G16B5/00
Domestic Patent References:
| WO2021163536A2 | 2021-08-19 |
Other References:
AZAD TAHA ET AL: "Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry", vol. 29, no. 6, 1 June 2021 (2021-06-01), US, pages 1984 - 2000, XP055862562, ISSN: 1525-0016, Retrieved from the Internet DOI: 10.1016/j.ymthe.2021.02.007
CHAKRABORTY SANDIPAN ED - NERI DARIO ET AL: "Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 534, 28 November 2020 (2020-11-28), pages 374 - 380, XP086429330, ISSN: 0006-291X, [retrieved on 20201128], DOI: 10.1016/J.BBRC.2020.11.075
ZAHRADNÍK JIRÍ ET AL: "SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution", NATURE MICROBIOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 6, no. 9, 16 August 2021 (2021-08-16), pages 1188 - 1198, XP037548549, DOI: 10.1038/S41564-021-00954-4
LANYING DU ET AL: "Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines", NATURE COMMUNICATIONS, vol. 7, 22 November 2016 (2016-11-22), pages 13473, XP055486939, DOI: 10.1038/ncomms13473
DICKEY THAYNE H. ET AL: "Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response", BIORXIV, 10 May 2021 (2021-05-10), XP055915754, Retrieved from the Internet [retrieved on 20220426], DOI: 10.1101/2021.05.09.443238
STARR TYLER N. ET AL: "Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding", vol. 182, no. 5, 1 September 2020 (2020-09-01), Amsterdam NL, pages 1295 - 1310.e20, XP055850377, ISSN: 0092-8674, Retrieved from the Internet DOI: 10.1016/j.cell.2020.08.012
TAI WANBO ET AL: "Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants", vol. 91, no. 1, 1 January 2017 (2017-01-01), US, XP055892495, ISSN: 0022-538X, Retrieved from the Internet DOI: 10.1128/JVI.01651-16
CHATTERJEE RAHUL ET AL: "Next-Generation Bioinformatics Approaches and Resources for Coronavirus Vaccine Discovery and Development-A Perspective Review", VACCINES, vol. 9, no. 8, 22 July 2021 (2021-07-22), pages 812, XP055915892, DOI: 10.3390/vaccines9080812
HARVEY WILLIAM T ET AL: "SARS-CoV-2 variants, spike mutations and immune escape", NATURE REVIEWS MICROBIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 19, no. 7, 1 June 2021 (2021-06-01), pages 409 - 424, XP037482862, ISSN: 1740-1526, [retrieved on 20210601], DOI: 10.1038/S41579-021-00573-0
RUI WANG ET AL: "Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, South Africa, and other COVID-19-devastated countries", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 21 March 2021 (2021-03-21), XP081910925
DUAN LIANGWEI ET AL: "The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens", FRONTIERS IN IMMUNOLOGY, vol. 11, 7 October 2020 (2020-10-07), XP055893073, DOI: 10.3389/fimmu.2020.576622
VERMA JYOTI ET AL: "A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics", ARCHIVES OF VIROLOGY, vol. 166, no. 3, 22 January 2021 (2021-01-22), pages 697 - 714, XP037369917, ISSN: 0304-8608, DOI: 10.1007/S00705-021-04961-Y
DESHPANDE ASHLESHA ET AL: "Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern", FRONTIERS IN IMMUNOLOGY, vol. 12, 4 June 2021 (2021-06-04), XP055915891, DOI: 10.3389/fimmu.2021.691715
CHAKRABORTY SANDIPAN ED - NERI DARIO ET AL: "Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 534, 28 November 2020 (2020-11-28), pages 374 - 380, XP086429330, ISSN: 0006-291X, [retrieved on 20201128], DOI: 10.1016/J.BBRC.2020.11.075
ZAHRADNÍK JIRÍ ET AL: "SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution", NATURE MICROBIOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 6, no. 9, 16 August 2021 (2021-08-16), pages 1188 - 1198, XP037548549, DOI: 10.1038/S41564-021-00954-4
LANYING DU ET AL: "Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines", NATURE COMMUNICATIONS, vol. 7, 22 November 2016 (2016-11-22), pages 13473, XP055486939, DOI: 10.1038/ncomms13473
DICKEY THAYNE H. ET AL: "Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response", BIORXIV, 10 May 2021 (2021-05-10), XP055915754, Retrieved from the Internet
STARR TYLER N. ET AL: "Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding", vol. 182, no. 5, 1 September 2020 (2020-09-01), Amsterdam NL, pages 1295 - 1310.e20, XP055850377, ISSN: 0092-8674, Retrieved from the Internet
TAI WANBO ET AL: "Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants", vol. 91, no. 1, 1 January 2017 (2017-01-01), US, XP055892495, ISSN: 0022-538X, Retrieved from the Internet
CHATTERJEE RAHUL ET AL: "Next-Generation Bioinformatics Approaches and Resources for Coronavirus Vaccine Discovery and Development-A Perspective Review", VACCINES, vol. 9, no. 8, 22 July 2021 (2021-07-22), pages 812, XP055915892, DOI: 10.3390/vaccines9080812
HARVEY WILLIAM T ET AL: "SARS-CoV-2 variants, spike mutations and immune escape", NATURE REVIEWS MICROBIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 19, no. 7, 1 June 2021 (2021-06-01), pages 409 - 424, XP037482862, ISSN: 1740-1526, [retrieved on 20210601], DOI: 10.1038/S41579-021-00573-0
RUI WANG ET AL: "Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, South Africa, and other COVID-19-devastated countries", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 21 March 2021 (2021-03-21), XP081910925
DUAN LIANGWEI ET AL: "The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens", FRONTIERS IN IMMUNOLOGY, vol. 11, 7 October 2020 (2020-10-07), XP055893073, DOI: 10.3389/fimmu.2020.576622
VERMA JYOTI ET AL: "A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics", ARCHIVES OF VIROLOGY, vol. 166, no. 3, 22 January 2021 (2021-01-22), pages 697 - 714, XP037369917, ISSN: 0304-8608, DOI: 10.1007/S00705-021-04961-Y
DESHPANDE ASHLESHA ET AL: "Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern", FRONTIERS IN IMMUNOLOGY, vol. 12, 4 June 2021 (2021-06-04), XP055915891, DOI: 10.3389/fimmu.2021.691715
Attorney, Agent or Firm:
KADOR & PARTNER PART MBB (DE)
Download PDF:
Previous Patent: METHOD FOR MATCHING A CANDIDATE IMAGE WITH A REFERENCE IMAGE
Next Patent: SHIFTING AND GEAR ASSEMBLY FOR TRANSMISSION
Next Patent: SHIFTING AND GEAR ASSEMBLY FOR TRANSMISSION